Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2018

View Archived Issues

Researchers present Fol-PRI-002 as a potential prodrug for oral administration

Uncovering the function of Cep57 in mosaic-variegated aneuploidy syndrome

MMP23B identified as a putative diagnostic biomarker of bladder cancer

Alnylam's RNAi therapeutic Onpattro for polyneuropathy of hATTR amyloidosis receives first approval

Pfizer describes new monoglyceride lipase inhibitors

University of Sydney and University of Technology, Sydney patent glycine transport inhibitors

Discovery of a potent and selective receptor antagonist for the treatment of asthma

FDA approves Galafold for Fabry disease

Orphazyme's arimoclomol enters phase III study for ALS

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery identify caspase inhibitors

MAP3K5 inhibitors identified by Fujian Cosunter Pharmaceutical Co., Medshine Discovery

Preventing fat uptake by lymphatic system could be antiobesity approach

TRK fusions actionable in blood cancers

Controlling HIV's reservoir

Progranulin as a novel therapeutic target for the treatment of frontotemporal dementia

Researchers identify novel candidate genes involved in cognitive function

PARP inhibitors may be ALS drugs

FDA approves The Population Council's 1-year contraceptive Annovera

Samsung Bioepis to soon begin phase I study of SB-26

First patients imaged in phase II expanded access study of 68Ga-PSMA-11

Iterum Therapeutics initiates phase III testing of sulopenem etzadroxil